A Randomized, Parallel Group, Open-Label, Multicenter Study to Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-01 (Betamethasone Dipropionate) Spray, 0.05%

Trial Profile

A Randomized, Parallel Group, Open-Label, Multicenter Study to Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-01 (Betamethasone Dipropionate) Spray, 0.05%

Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Mar 2018

At a glance

  • Drugs DFD 01 (Primary) ; Corticosteroid
  • Indications Plaque psoriasis
  • Focus Adverse reactions
  • Sponsors Promius Pharma
  • Most Recent Events

    • 14 Feb 2018 Planned number of patients changed from 75 to 50.
    • 14 Feb 2018 Planned End Date changed from 1 Mar 2018 to 1 Dec 2018.
    • 14 Feb 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top